Avapritinib is a new TKI designed on the base of its selectively property to target the active conformation of KIT and PDGFRA. A phase I clinical trial (ClinicalTrials.gov No. NCT02508532) has recently assessed its safety, tolerability, and anti‐tumor activity (Heinrich et al, 2020). This evidence concerns the gene PDGFRA and neoplasm.